Wednesday, 18 November 2026European Markets

VIVORYON Stock Impressive Rise On Wednesday, Outperforms Market

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(VIANEWS) - The Market ended the session with VIVORYON (VVY.AS) jumping 26.39% to €0.91 on Wednesday while AEX-Index slid 0.09% to €874.02.

About VIVORYON

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.

Earnings Per Share

As for profitability, VIVORYON has a trailing twelve months EPS of €-1.12.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VIVORYON's stock is considered to be oversold (<=20).

Volume

Today's last reported volume for VIVORYON is 2740500 which is 327.83% above its average volume of 640554.

Volatility

VIVORYON's last week, last month's, and last quarter's current intraday variation average was 14.98%, 1.67%, and 4.37%.

VIVORYON's highest amplitude of average volatility was 16.85% (last week), 5.33% (last month), and 4.37% (last quarter).

More news about VIVORYON (VVY.AS).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 24 Apr 2024
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›